OSE IMMUNOTHERAPE.EO -20
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II c… Read more
OSE IMMUNOTHERAPE.EO -20 (6OP) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, OSE IMMUNOTHERAPE.EO -20 (6OP) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
OSE IMMUNOTHERAPE.EO -20 - Net Assets Trend (None–None)
This chart illustrates how OSE IMMUNOTHERAPE.EO -20's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for OSE IMMUNOTHERAPE.EO -20 (None–None)
The table below shows the annual net assets of OSE IMMUNOTHERAPE.EO -20 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to OSE IMMUNOTHERAPE.EO -20's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
OSE IMMUNOTHERAPE.EO -20 Competitors by Market Cap
The table below lists competitors of OSE IMMUNOTHERAPE.EO -20 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Muhak Co. Ltd
KO:033920
|
$59.30 Million |
|
Lizhi Inc
NASDAQ:SOGP
|
$59.32 Million |
|
Kyobo With Special Purpose Acq
KQ:205100
|
$59.35 Million |
|
Alithya Group Inc
NASDAQ:ALYAF
|
$59.40 Million |
|
MEDEXUS PHARMACEUTIC.
F:P731
|
$59.28 Million |
|
Prosegur Compañía de Seguridad S.A
PINK:PGCSF
|
$59.27 Million |
|
Waldencast Acquisition Corp
NASDAQ:WALD
|
$59.26 Million |
|
Aldebaran Resources Inc
OTCQX:ADBRF
|
$59.25 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in OSE IMMUNOTHERAPE.EO -20's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares OSE IMMUNOTHERAPE.EO -20's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently OSE IMMUNOTHERAPE.EO -20 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares OSE IMMUNOTHERAPE.EO -20's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $338,657,802
- Average return on equity (ROE) among peers: -66.32%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| OSE IMMUNOTHERAPE.EO -20 (6OP) | €- | N/A | N/A | $59.28 Million |
| 09R (09R) | $-2.13 Million | 0.00% | 0.00x | $10.61 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| Argen-X (1AE) | $4.10 Billion | -7.20% | 0.11x | $38.55 Billion |
| 1S90 (1S90) | $131.51 Million | -49.87% | 1.70x | $52.41 Million |
| Strategic Partners A/S (1TB0) | $19.25 Million | -1.55% | 0.22x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.50 Million |
| Intervacc AB (publ) (2E9) | $162.33 Million | -46.52% | 0.15x | $3.64 Million |
| 2F5 (2F5) | $-1.76 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $3.03 Million | -558.03% | 2.82x | $8.56 Million |